Skip to main content

Table 3 Patient characteristics

From: Integrating the patient voice with clinician reports to identify a hepatocellular carcinoma-specific subset of treatment-related symptomatic adverse events

 

Total

(N = 17)

Age, years

 Mean (SD)

68.8 (8.5)

 Median

68

 Min-max

54–84

Sex

 Male

15 (88.2%)

 Female

2 (11.8%)

Race

 White

13 (76.4%)

 Black or African American

2 (11.8%)

 Asian

0

 Native Hawaiian or other Pacific Islander

0

 American Indian or Alaskan native

0

 Other

1 (5.9%)

 Not reported

1 (5.9%)

Ethnicity

 Hispanic or Latino

2 (11.8%)

 Not Hispanic or Latino

13 (76.4%)

 Not reported

2 (11.8%)

Living situation

 Living alone

6 (35.3%)

 Living with partner or spouse, family, or friends

9 (52.9%)

 Other

1 (5.9%)

 Not reported

1 (5.9%)

Employment status

 Employed full time

1 (5.9%)

 Employed part time

0

 Unemployed

1 (5.9%)

 Retired

10 (58.8%)

 Disabled

2 (11.8%)

 Other

2 (11.8%)

 Not reported

1 (5.9%)

Education levela

 Secondary/high school

2 (11.8%)

 Some college

7 (41.2%)

 College degree

4 (23.5%)

 Postgraduate degree

2 (11.8%)

 Other or Missing

2 (11.8%)

General health (past week)

 Very good

3 (17.7%)

 Good

6 (35.3%)

 Fair

5 (29.4%)

 Poor

2 (11.8%)

 Very poor

0

 Not reported

1 (5.9)

Child-Pugh class

 A—with no locoregional treatment

3 (17.7%)

 A—with locoregional treatment but before sorafenib treatment

4 (23.5%)

 A—after sorafenib treatment

3 (17.7%)

 B—with any treatment experience

7 (41.2%)

ECOG performance status

 0

8 (47.1%)

 1

9 (52.9%)

Comorbiditiesa

 Asthma

2 (11.8%)

 Anxiety/depression

5 (29.4%)

 Arthritis

3 (17.7%)

 COPD (emphysema, chronic bronchitis)

3 (17.7%)

 Diabetes

4 (23.5%)

 Hypertension (high blood pressure)

10 (58.8%)

 Chest pain/abdominal pain

1 (5.9%)

 No other health conditions

2 (11.8%)

HCC treatments receiveda

 Chemotherapy

2 (11.8%)

 Transarterial chemoembolization

5 (29.4%)

 External radiation

1 (5.9%)

 Ablation

8 (47.1%)

 Liver resection

4 (23.5%)

 Y90 radioembolization

6 (35.3%)

 Sorafenib

5 (29.4%)

Current medicationsa

 Antibiotics

2 (11.8%)

 Nutritional support

2 (11.8%)

 Pain medications/corticosteroids/anti-inflammatory agents

5 (29.4%)

 Drugs for gastrointestinal-related disorders

6 (35.3%)

 Drugs for anemia

1 (5.9%)

 None

2 (11.8%)

  1. COPD, chronic obstructive pulmonary disease; ECOG, Eastern Cooperative Oncology Group; HCC, hepatocellular carcinoma
  2. aNot mutually exclusive